Home > Jean-François Korobelnik, AAO 2018 – Aflibercept and the APOLLON Study
Diabetic Macular Oedema, Retina/Vitreous

Jean-François Korobelnik, AAO 2018 – Aflibercept and the APOLLON Study

Published Online: November 23rd 2018

Professor Jean-François Korobelnik joins us to discuss aflibercept and its effectiveness as a widely used and well-tolerated anti-vascular endothelial growth factor (VEGF) inhibitor. He also briefly describes the APOLLON study, looking at the real-life treatment, monitoring and outcomes of treatment in patients with diabetic macular edema in routine clinical practice.

1. What advantages does aflibercept offer compared with other anti-vascular endothelial growth factor (VEGF) therapies in diabetic macular edema (DME)? (0:11)
2. Could you tell us a little about the design of the APOLLON study? (0:34)
3. How do injection frequencies in real-world studies differ from those in randomised clinical trials? (1:20)
4. What have been the six-month findings of this study? (2:08)
5. What are the clinical implications of these findings and what future studies are planned? (2:52)

Speaker disclosures: Jean-François Korobelnik has nothing to disclose in relation to this interview.

Filmed at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting, Chicago, IL, US, 27–30 October 2018.

Share this Video
Related Videos In Retina/Vitreous
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar